Knodler, M., Korfer, J., Kunzmann, V., Trojan, J., Daum, S., Schenk, M., Kullmann, F., Schroll, S., Behringer, D., Stahl, M., Al-Batran, S.E., Hacker, U., Ibach, S., Lindhofer, H. and Lordick, F. (2018) Randomised Phase II Trial to Investigate Catumaxomab (Anti-EpCAM × Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients with Gastric Cancer. British Journal of Cancer, 119, 296-302.
https://doi.org/10.1038/s41416-018-0150-6

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.